High chemo dosage improves survival for AML patients

12/5/2008 | Yahoo!

Research shows a higher dose of the chemotherapy drug daunorubicin increased median survival rates for patients with previously untreated acute myeloid leukemia, when compared with using the standard dosage. Patients in the high-dose group had overall survival of 23.7 months, compared to 15.1 months for patients in the standard-dose group.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations